Home » Privacy Policy

Privacy policy

Salix Pharmaceuticals, Inc. Internet Privacy Statement

Salix Pharmaceuticals, Inc. ("Salix"), respects the privacy of visitors to our site (the "Site") and is committed to maintaining your privacy when you visit. Salix will only collect your personally identifiable information when you voluntarily provide it to us. From time to time, we may refer to this information to better understand your needs and how we can improve our services. We may use this information to contact you; however we will not sell the personally identifiable information you provide to us at this Web site to any third parties for their own use.

As many other companies do, Salix also measures the performance of its Site in order to improve and customize it in favor of our visitors. Salix's Web site may use a technology called "cookies". Generally, a cookie assigns a unique number to the visitor which has no meaning outside the assigning site. The purpose of this technology and the information it provides is to help us improve our site. Most Web browsers allow the user to deny or accept the cookie feature. Please note that cookies may be necessary to provide you with certain features available on the Salix Site. In all cases in which cookies are used, neither Salix nor any third party will use the cookie to collect personally identifiable information unless you voluntarily agree to enter the information.

Salix's Web site may also maintain Web server logs that can automatically identify your computer by its IP address and collect that information. An IP address is a number that is automatically assigned to your computer by your Internet service provider. Salix's Web server logs may collect statistical data that is generated by your computer when it visits Salix's Web site, such as the type of Web browser used to access the Site and the pages you visit. No personally identifiable information would be contained in these Web server logs.

Some services on our Site may require registration. When you register, you may need to complete certain fields, as well as choose a user name and password. In these situations, if you choose to withhold any personally identifiable information requested by us, it may not be possible for you to gain access to certain parts of the Site and for us to respond to your query. Please see our Terms and Conditions for more information.

The privacy policy does not apply to those sites to which the Salix Site may provide links. You should contact those sites directly for information on their privacy policies. Salix reserves its right to amend this policy at any time.

This Site is intended for U.S. residents only.

Created 7/02

Revised 3/10

IMPORTANT SAFETY INFORMATION

XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥18 years of age. In the trials of XIFAXAN for HE, 91% of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores >25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon which may lead to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

The most common adverse reactions occurring in >8% of patients in the clinical study were edema peripheral (15%), nausea (14%), dizziness (13%), fatigue (12%), ascites (11%), muscle spasms (9%), pruritus (9%), and abdominal pain (9%).

Complete Prescribing Information.

For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: Salix@medcomsol.com